- Home
- IINN vs IMNN Comparison
IINN vs IMNN Comparison
Compare IINN & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IINN
- IMNN
- Stock Information
- Founded
- IINN 2018
- IMNN 1982
- Country
- IINN Israel
- IMNN United States
- Employees
- IINN N/A
- IMNN N/A
- Industry
- IINN Medical/Dental Instruments
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- IINN Health Care
- IMNN Health Care
- Exchange
- IINN Nasdaq
- IMNN Nasdaq
- Market Cap
- IINN 13.7M
- IMNN 12.1M
- IPO Year
- IINN 2021
- IMNN 1985
- Fundamental
- Price
- IINN $0.85
- IMNN $0.77
- Analyst Decision
- IINN Strong Buy
- IMNN Buy
- Analyst Count
- IINN 1
- IMNN 2
- Target Price
- IINN $2.00
- IMNN $14.00
- AVG Volume (30 Days)
- IINN 422.8K
- IMNN 5.4M
- Earning Date
- IINN 08-14-2025
- IMNN 08-13-2025
- Dividend Yield
- IINN N/A
- IMNN N/A
- EPS Growth
- IINN N/A
- IMNN N/A
- EPS
- IINN N/A
- IMNN N/A
- Revenue
- IINN N/A
- IMNN N/A
- Revenue This Year
- IINN N/A
- IMNN N/A
- Revenue Next Year
- IINN N/A
- IMNN N/A
- P/E Ratio
- IINN N/A
- IMNN N/A
- Revenue Growth
- IINN N/A
- IMNN N/A
- 52 Week Low
- IINN $0.40
- IMNN $0.37
- 52 Week High
- IINN $1.60
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- IINN 63.38
- IMNN 40.14
- Support Level
- IINN $0.70
- IMNN $0.93
- Resistance Level
- IINN $0.77
- IMNN $1.03
- Average True Range (ATR)
- IINN 0.06
- IMNN 0.18
- MACD
- IINN 0.01
- IMNN -0.10
- Stochastic Oscillator
- IINN 75.80
- IMNN 1.39
About IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).